<unk>  was a drug that was approved for the treatment of relapsed or chemotherapy/rituxan-refractory Non-Hodgkin lymphoma in 2003.  It was sold in the U.S. and Canada under the trade name Bexxar.  Sale of the drug was discontinued and marketing approval was withdrawn in February 2014 due to the decline in usage (fewer than 75 patients in 2012) and the existence of other similar drugs.
This drug combination was developed by Corixa which was purchased by GlaxoSmithKline) in 2005.
Tositumomab
Acalabrutinib
Blinatumomab
Volociximab
Ibritumomab tiuxetan
Fostamatinib
Afatinib
Bavituximab